Clinical Trial Update: A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. [Phase 2, Phase 3]

View source ↗

Summary

The randomized, double-blind, placebo-controlled Aldafermin trial for Primary Sclerosing Cholangitis (NCT06654726) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• Aldafermin (aldafermin)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Primary Sclerosing Cholangitis | Phase 2, Phase 3 | Status: WITHDRAWN